Scaling cryopreservation has become a major obstacle in the path toward commercializing cell and gene therapies. In a recent survey conducted by the ISCT Cold Chain Working Group, respondents identified “ability to process at large scale” as the most significant challenge facing cryopreservation today. As manufacturing expands to support higher volumes, the industry is grappling with key variables—such as batch size, sub-batching risks, CPA incubation timing, and cytotoxicity management—that directly impact product quality and process reproducibility.

This webinar will feature a panel of experts offering insights across three critical perspectives: technology innovations, allogeneic therapy workflows, and autologous manufacturing considerations. Each panelist will present a short slide deck to share lessons learned, operational pain points, and potential solutions from their area of focus. The session will conclude with a moderated discussion and audience Q&A, providing attendees with actionable insights into how the field is working to overcome this bottleneck.

Key Learning Objectives: